TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing ...

Relay Therapeutics, Inc. ( NASDAQ: RLAY) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Good morning, everyone, and welcome to Morgan Stanley Global Healthcare ...

Nemvaleukin alfa shows promising antitumor activity in advanced melanoma and renal cell carcinoma, with manageable safety in ...

Bariatric surgery increases 1-year acute kidney injury and 10-year nephrolithiasis risks but reduces chronic kidney disease and kidney failure risks compared with no surgery in a Danish registry study ...

Sight Sciences, Inc. ( NASDAQ: SGHT) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:50 PM EDT ...

Boston Consulting Group finds AAAP on track to shape $25 billion in climate-resilient investments, benefiting nearly 200 million people across Africa.Rotterdam, Sept. 12, 2025and its GCA-led Upstream ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1Filing based on four Phase 3 studies that met all primary and co-primary endpoints. Th ...

Tegoprazan has comparable efficacy to proton pump inhibitors for H pylori eradication, with added benefit in clarithromycin-resistant strains.

Results from the Phase III STRIDE-13 trial (NCT06177912) showed that Merck’s Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) demonstrated robust immune responses in children and adolescents aged ...

Planning and fund-raising for the “Cultural Olympiad,” the arts programming that is part of the 2028 games, should have been well underway by now, several experts say. By Robin Pogrebin On the 40th ...